Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
- Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
Copenhagen, Denmark; July 21, 2021 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 1,433 million in the second quarter of 2021. - Net trade sales were USD 770 million in the U.S. and USD 663 million in the rest of the world.
- Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize daratumumab.
- Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.